Objective  To analyze the clinical characteristics of COVID-19 patients and the changes in their myocardial biomarkers. 

Methods  The clinical data of COVID-19 patients admitted to the First People's Hospital of Jiangxia District in Wuhan, China, from February 1, 2020, to March 15, 2020, were retrospectively collected, and the differences in clinical symptoms and laboratory biomarkers were compared between ICU and non-ICU patients with COVID-19. 

Results  A total of 135 COVID-19 pa-tients were included, with 30 patients in the ICU group and 105 patients in the non-ICU group. The age (64.0 years vs. 54.0 years) and the proportion of patients with comorbidity (56.7% vs. 27.6%) in the ICU group were significantly higher than in the non-ICU group, there were no significant differences in gen-der. In terms of clinical symptoms, the incidence of clinical symptoms in the ICU group was generally slightly higher than that in non-ICU group, but the only statistically significant difference was in dysp-nea symptom. The count of leukocytes, percentage of neutrophils, the level of alanine aminotransferase, aspartate aminotransferase, urea nitrogen, creatine kinase isoenzyme, myoglobin, and lactate dehydrogenase, and the propor-tion of patients with abnormal levels of the above indicators in the ICU group were significantly higher than those in non-ICU group. Among ICU patients, the levels of troponin T, creatine kinase isoenzyme, myoglobin, and the propor-tion of patients with abnormal levels of above indicators were significantly higher in dead patients than those of sur-viving patients. 

Conclusion  Elderly COVID-19 patients with comorbidity are at high risk of severe pneumonia, and abnormal levels of myocardial injury biomarkers in COVID-19 patients are correlated with the severity and prognosis.

1.World Health Organization. WHO director-general's remarks at the media briefing on 2019-nCoV (2020) [EB/OL]. (2020-02-11) [Access on 2020-03-26]. https://www.who.int/dg/ speech-es/detail/who-director-general-s-remarks-at-themedia-briefing-on-2019-nCoV-on-11-february-2020.

2.中华人民共和国国家卫生健康委员会. 国家卫生健康委关于修订新型冠状病毒肺炎英文命名事宜的通知[EB/OL]. (2020-02-22) [Access on 2020-03-01]. http://www.nhc.gov.cn/yzygj/s7653p/202002/33393aa53d984ccdb1053a52b6bef810.shtml.

3.Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel corona-virus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523. DOI: 10.1016/S0140-6736(20)30154-9.

4.Sahu KK, Mishra AK, Lal A. COVID-19: update on epidemiology, disease spread and management[J]. Monaldi Arch Chest Dis, 2020, 90(1): 197-205. DOI: 10.4081/mo naldi.2020.1292.

5.Falaschi Z, Danna PS, Arioli R, et al. Chest CT accuracy in diagnosing COVID-19 during the peak of the Italian epidemic: a retrospective correlation with RT-PCR testing and analysis of discordant cases[J].  Eur J Radiol, 2020, 130: 109192. DOI: 10.1016/j.ejrad.2020.109192.

6.Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and periph-eral blood mononuclear cells in COVID-19 patients[J]. Emerg Microbes Infect, 2020, 9(1): 761-770. DOI: 10.1080/ 22221751.2020.1747363.

7.卫生健康委办公厅, 中医药局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案（试行第五版）的通知[EB/OL]. (2020-02-04) [Access on 2020-03-17]. http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm.

8.de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging corona-viruses[J]. Nat Rev Microbiol, 2016, 14(8): 523-534. DOI: 10.1038/nrmicro.2016.81.

9.Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel corona-virus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11): 1061-1069. DOI: 10.1001/jama[1].2020.1585.

10.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. The Lancet, 2020, 395(10229): 1054-1062. DOI: 10.1016/s0140-6736(20) 30566-3. 

11.Chen X, Zhang G, Hao SY, et al. Similarities and differences of early pulmonary CT features of pneumo-nia caused by SARS-CoV-2, SARS-CoV and MERS-CoV: comparison based on a systemic review[J]. Chin Med Sci J, 2019, 35(3): 254-261. DOI: 10.24920/003727.

12.Kumar S, Gattani SC, Baheti AH, et al. Comparison of the performance of APACHE II, SOFA, and mNUTRIC scoring systems in critically ill patients: a 2-year cross-sectional study[J]. Indian J Crit Care Med, 2020, 24(11): 1057-1061. DOI: 10.5005/JP-JOURNALS-10071-23549.

13.Gemmati D, Bramanti B, Serino ML, et al. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. might the double X-Chromosome in females be protective against SARS-CoV-2 compared to the single X-Chromosome in males?[J]. Int J Mol Sci, 2020, 21(10): 3474. DOI: 10.3390/ijms21103474.

14.赵军宁, 戴瑛, 华桦, 等. 治疗新冠病毒肺炎(COVID-19)中药"药理谱-云"特点与有效性评价要素[J]. 中药药理与临床, 2020, 36(1): 2-12. DOI: 10.13412/j.cnki.zyyl.20200313.002. [Zhao JN, Dai Y, Hua H, et al. "Pharmacologi-cal spectrum-cloud" characteristics and effectiveness evaluation factors of traditional Chinese medi-cine for COVID-19[J]. Pharmacology and Clinics of Chinese Materia Medica, 2020, 36(1): 2-12.]

15.Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system[J]. Circ Res, 2020, 126(10): 1456-1474. DOI: 10.1161/circresaha. 120.317015.

16.王慧, 高振, 林跃家, 等. 既往病毒性呼吸道传染疾病研究对抗COVID-19药物研发的启示[J]. 中国现代应用药学, 2020, 37(5): 513-524. DOI: 10.13748/j.cnki.issn1007-7693.2020.05.001. [Wang H, Gao Z, Lin YJ, et al. Im-plications of previous studies on viral respiratory infections for anti-COVID-19 drug development [J]. Chinese Journal of Modern Applied Pharmacy, 2020, 37(5): 513-524.]

17.Bilinska K, Jakubowska P, Von Bartheld CS, et al. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age[J]. ACS Chem Neurosci, 2020, 11(11): 1555-1562. DOI: 10.1021/acschemneuro.0c00210.

18.王文辰, 夏彦明, 朱建飞, 等. 血管紧张素转换酶2在人类高致病性冠状病毒肺炎中作用的研究进展[J]. 中国胸心血管外科临床杂志, 2020, 27(5): 588-596. DOI: 10.7507/1007-4848.202003004. [Wang WC, Xia YM, Zhu JF, et al. Research progress of the role of angiotensin-converting enzyme 2 (ACE2) in the highly pathogenic human coronavirus pneumonia[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(5): 588-596.]

19.马青龙, 张立婷, 杨文柯, 等. 新型冠状病毒细胞受体ACE2的研究进展[J]. 兰州大学学报(医学版), 2020, 46(2): 70-75. DOI: 10.13885/j.issn.1000-2812.2020. 02.013. [Ma QL, Zhang LT, Yang WK, et al. Advances in the development of severe acute respiratory syndrome coronavirus 2 cell receptor ACE2[J]. Journal of Lanzhou University (Medical Sciences), 2020, 46(2): 70-75.]

20.Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)[J]. Mil Med Res, 2020, 7(1): 4. DOI: 10.1186/s40779-020-0233-6.

21.Zhang H, Penninger JM, Li Y. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: mo-lecular mechanisms and potential therapeutic target[J]. Intensive Care Med, 2020, 46(4): 586-590. DOI: 10.1007/s00134-020-05985-9.

22.Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5(7): 811-818. DOI: 10.1001/jamacardio.2020.1017.

23.Xue J, Zheng J, Shang X, et al. Risk factors for prolonged viral clearance in adult patients with COVID-19 in Beijing, China: a prospective observational study[J]. Int Immunopharmacol, 2020, 89(Pt A): 107031. DOI: 10.1016/j.intimp.2020.107031.

24.Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China[J]. JAMA Cardiol, 2020, 5(7): 802-810. DOI: 10.1001/jamacardio.2020.0950.

25.Yang Y, Hu X, Xiong L, et al. Clinical characteristics of hospitalized mild/moderate COVID-19 patients with a prolonged negative conversion time of SARS-CoV-2 nucleic acid detection[J]. BMC Infect Dis, 2021, 21(1): 141. DOI: 10.1186/s12879-021-05851-z.